These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 11005703)

  • 1. Comparative tolerability of the HMG-CoA reductase inhibitors.
    Farmer JA; Torre-Amione G
    Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase inhibitors and myotoxicity.
    Ucar M; Mjörndal T; Dahlqvist R
    Drug Saf; 2000 Jun; 22(6):441-57. PubMed ID: 10877038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.
    Martin JE; Cavanaugh TM; Trumbull L; Bass M; Weber F; Aranda-Michel J; Hanaway M; Rudich S
    Clin Transplant; 2008; 22(1):113-9. PubMed ID: 18217912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
    Stein EA
    Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
    Vermes A; Vermes I
    Am J Cardiovasc Drugs; 2004; 4(4):247-55. PubMed ID: 15285699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
    Kocarek TA; Reddy AB
    Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis and statin therapy: relevance to the elderly.
    Sica DA; Gehr TW
    Am J Geriatr Cardiol; 2002; 11(1):48-55. PubMed ID: 11773716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Desager JP; Horsmans Y
    Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.